Drugs / VU319
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04051801 | May 2021 | cognitive disorder | Vanderbilt University Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT03220295 | Jul 2017 → Oct 2019 | cognitive disorder | Vanderbilt University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VU319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03220295 ↗ |
| Known as | VU0467319 | “Herein we detail the first disclosure of VU0467319 (VU319), an M1 Positive Allosteric Modulator (PAM) clinical candidate that successfully completed a Phase I Single Ascending...” PMID 39660766 ↗ Dec 20241“Multiple Ascending Dose Phase I Study of the M1 Positive Allosteric Modulator VU0467319” NCT04051801 ↗ |
| Action | Activate | “M1 Positive Allosteric Modulator” NCT04051801 ↗ |
| Route | Oral | “Volunteers will receive oral VU319 single dose administration in the fasted state.” NCT03220295 ↗ |